Cleonisio Leite Rodrigues
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cleonisio Leite Rodrigues has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Lara Albuquerque de Brito
Hospital Geral de Fortaleza Fortaleza Ceará Brazil
3 shared publications - Hermany Capistrano Freitas
Hospital Geral de Fortaleza, Serviço de Neurologia, Fortaleza CE, Brazil
2 shared publications - Marcondes Cavalcante França
Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil
2 shared publications - Wilson Marques
Department of Neuroscience and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, São Paulo, Brazil
2 shared publications - Acary Souza Bulle Oliveira
Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo SP, Brazil
1 shared publication - Alexandre Braga Libório
Medical Sciences Postgraduate Program, Universidade de Fortaleza- UNIFOR, Fortaleza, Ceará, Brazil
1 shared publication
Latest Publications
- Open Access
- 28 August 2026
- Published by Wiley in Journal of the Peripheral Nervous System
- Vol. 31 (3)
Neuropathy in Val122Ile Hereditary Transthyretin ( ATTR ) Amyloidosis: A Multicenter Retrospective Cohort Study
Background and Aims: The Val122Ile ATTR Amyloidosis has traditionally been linked to cardiac manifestations. Recent studies suggest that neuropathy may be relevant. In this study, we characterized its peripheral nerve manifestations in depth. Methods: This was a national, multicenter, observational, retrospective study. Patients underwent careful clinical and neurophysiological evaluation. We excluded those with alternative etiologies. Results: We identified 246 Val122Ile carriers, including 240 heterozygous, 4 homozygous, and 2 compound heterozygous. Gender distribution was similar. Age of onset: 19–89 years, mean 53 ± 17. Self‐reported ethnicity: White (26.7%), Black (17.3%), and Mixed (Pardo) (56.0%). Birthplaces spanned all Brazilian regions, mainly the Northeast. Among heterozygotes, 52 of 122 (42.6%) were symptomatic. Carpal tunnel syndrome (CTS) preceded polyneuropathy and/or cardiomyopathy in 69.2%. The most frequent onset manifestations, excluding CTS, were cardiomyopathy (52.9%), neuropathy (37.3%), and mixed phenotype (9.8%). Age of onset: 29–86 years (mean: 64.9 years). During follow‐up, 14/27 cardiac patients developed neuropathy, and 8/19 neurologic patients developed cardiomyopathy, significantly increasing the mixed phenotype from 9.8% to 52.9%. Most patients with neuropathy presented with sensory or sensory and motor disease (62.2%), followed by small fiber neuropathy (32.4%), and isolated dysautonomia (5.4%). Interpretation: Neuropathy is underrecognized in Val122Ile ATTR Amyloidosis, is frequent at disease onset, may be the sole manifestation, and may occur in White persons. CTS frequently preceded neuropathy, usually an axonal polyneuropathy, although atypical patterns were observed. This variant clusters in the Northeast region of Brazil.
- 28 August 2026
- Published by Wiley in Journal of the Peripheral Nervous System
- Vol. 31 (3)
Open AccessNeuropathy in Val122Ile Hereditary Transthyretin ( ATTR ) Amyloidosis: A Multicenter Retrospective Cohort Study
Background and Aims: The Val122Ile ATTR Amyloidosis has traditionally been linked to cardiac manifestations. Recent studies suggest that neuropathy may be relevant. In this study, we characterized its peripheral nerve manifestations in depth. Methods: This was a national, multicenter, observational, retrospective study. Patients underwent careful clinical and neurophysiological evaluation. We excluded those with alternative etiologies. Results: We identified 246 Val122Ile carriers, including 240 heterozygous, 4 homozygous, and 2 compound heterozygous. Gender distribution was similar. Age of onset: 19–89 years, mean 53 ± 17. Self‐reported ethnicity: White (26.7%), Black (17.3%), and Mixed (Pardo) (56.0%). Birthplaces spanned all Brazilian regions, mainly the Northeast. Among heterozygotes, 52 of 122 (42.6%) were symptomatic. Carpal tunnel syndrome (CTS) preceded polyneuropathy and/or cardiomyopathy in 69.2%. The most frequent onset manifestations, excluding CTS, were cardiomyopathy (52.9%), neuropathy (37.3%), and mixed phenotype (9.8%). Age of onset: 29–86 years (mean: 64.9 years). During follow‐up, 14/27 cardiac patients developed neuropathy, and 8/19 neurologic patients developed cardiomyopathy, significantly increasing the mixed phenotype from 9.8% to 52.9%. Most patients with neuropathy presented with sensory or sensory and motor disease (62.2%), followed by small fiber neuropathy (32.4%), and isolated dysautonomia (5.4%). Interpretation: Neuropathy is underrecognized in Val122Ile ATTR Amyloidosis, is frequent at disease onset, may be the sole manifestation, and may occur in White persons. CTS frequently preceded neuropathy, usually an axonal polyneuropathy, although atypical patterns were observed. This variant clusters in the Northeast region of Brazil.
- Open Access
- 12 May 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (06) , 001-005
Optimizing myasthenia gravis management in practice: integrating clinical scales and classification systems
Myasthenia gravis is an antibody-mediated disorder of the neuromuscular junction. Fatigability and fluctuations are hallmarks of the disease, posing a challenge: evaluation through a single physical examination may not reflect disease control. A shift towards patient-reported Outcomes is a new paradigm in the current practice, and these outcomes are usually assessed through validated scales. In the present paper, we discuss some of the most used scales in the clinical practice, such as the Myasthenia Gravis Foundation of America (MGFA) scale, the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, and the 15-Item Myasthenia Gravis Quality of Life (MG-QOL15) scale. Definitions of remission, minimal manifestation, high-burden disease, highly-active disease, and others are reviewed, and correlations involving these definitions and the scales are presented. Guidance on how to assess disease severity, therapeutic response, and a rationale for treatment escalation are explored.
- 12 May 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (06) , 001-005
Open AccessOptimizing myasthenia gravis management in practice: integrating clinical scales and classification systems
Myasthenia gravis is an antibody-mediated disorder of the neuromuscular junction. Fatigability and fluctuations are hallmarks of the disease, posing a challenge: evaluation through a single physical examination may not reflect disease control. A shift towards patient-reported Outcomes is a new paradigm in the current practice, and these outcomes are usually assessed through validated scales. In the present paper, we discuss some of the most used scales in the clinical practice, such as the Myasthenia Gravis Foundation of America (MGFA) scale, the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, and the 15-Item Myasthenia Gravis Quality of Life (MG-QOL15) scale. Definitions of remission, minimal manifestation, high-burden disease, highly-active disease, and others are reviewed, and correlations involving these definitions and the scales are presented. Guidance on how to assess disease severity, therapeutic response, and a rationale for treatment escalation are explored.
- Open Access
- 24 March 2026
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 81, 105076
Letter to the editor: Comment on “Involvement of cranial nerves in ATTR Ile127Val amyloidosis” by Silva Batista JAD et al. (Eur J Med Genet. 2022 Jul;65(7):104524) and report of 3 new patients
- 24 March 2026
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 81, 105076
Open AccessLetter to the editor: Comment on “Involvement of cranial nerves in ATTR Ile127Val amyloidosis” by Silva Batista JAD et al. (Eur J Med Genet. 2022 Jul;65(7):104524) and report of 3 new patients
- 18 December 2025
- Published by Taylor & Francis in Amyloid
- p. 1-4
Endothelial glycocalyx disruption and early renal tubular injury in hereditary transthyretin Amyloidosis with dysautonomia
- 18 December 2025
- Published by Taylor & Francis in Amyloid
- p. 1-4
Endothelial glycocalyx disruption and early renal tubular injury in hereditary transthyretin Amyloidosis with dysautonomia
- Open Access
- 10 October 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (20) , 2556
Peripheral Nerve Ultrasound Findings in Hereditary Transthyretin Amyloidosis in Brazil
Background/Objectives: Hereditary transthyretin amyloidosis (ATTRv) is an autosomal dominant disorder characterized by systemic deposition of amyloid fibrils, leading to peripheral neuropathy and multisystemic involvement. Peripheral nerve ultrasound is a promising tool for detecting structural nerve changes, yet its use in Latin American populations is limited. This study aimed to characterize nerve ultrasound findings in Brazilian patients with ATTRv. Methods: We conducted a cross-sectional study of 72 genetically confirmed ATTRv individuals from two Brazilian centers. Participants were classified into symptomatic patients with polyneuropathy (n = 31) and asymptomatic TTR variant carriers (n = 41). All participants underwent a standardized neurological examination, and nerve ultrasound was used to assess the median nerve, brachial plexus, and C6 root. Cross-sectional areas (CSAs) from the right side were used for analysis and compared to reference values. Results: Symptomatic patients showed increased CSAs in the median nerve (wrist: 10.17 mm2, arm: 9.8 mm2), C6 root (8.55 mm2), and brachial plexus (70.82 mm2; all p < 0.05), but not in the forearm. Notably, asymptomatic carriers exhibited nerve enlargement in the median nerve at the wrist, the C6 root, and the brachial plexus, despite lacking clinical signs of neuropathy. Peripheral nerve enlargement in ATTRv affects both symptomatic patients and asymptomatic carriers, with a predilection for proximal and entrapment sites. Conclusions: These findings support the utility of nerve ultrasound as a non-invasive biomarker for early nerve involvement in ATTRv. Further studies are warranted to validate its role in disease monitoring and guide therapeutic interventions, especially in genetically at-risk populations.
- 10 October 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (20) , 2556
Open AccessPeripheral Nerve Ultrasound Findings in Hereditary Transthyretin Amyloidosis in Brazil
Background/Objectives: Hereditary transthyretin amyloidosis (ATTRv) is an autosomal dominant disorder characterized by systemic deposition of amyloid fibrils, leading to peripheral neuropathy and multisystemic involvement. Peripheral nerve ultrasound is a promising tool for detecting structural nerve changes, yet its use in Latin American populations is limited. This study aimed to characterize nerve ultrasound findings in Brazilian patients with ATTRv. Methods: We conducted a cross-sectional study of 72 genetically confirmed ATTRv individuals from two Brazilian centers. Participants were classified into symptomatic patients with polyneuropathy (n = 31) and asymptomatic TTR variant carriers (n = 41). All participants underwent a standardized neurological examination, and nerve ultrasound was used to assess the median nerve, brachial plexus, and C6 root. Cross-sectional areas (CSAs) from the right side were used for analysis and compared to reference values. Results: Symptomatic patients showed increased CSAs in the median nerve (wrist: 10.17 mm2, arm: 9.8 mm2), C6 root (8.55 mm2), and brachial plexus (70.82 mm2; all p < 0.05), but not in the forearm. Notably, asymptomatic carriers exhibited nerve enlargement in the median nerve at the wrist, the C6 root, and the brachial plexus, despite lacking clinical signs of neuropathy. Peripheral nerve enlargement in ATTRv affects both symptomatic patients and asymptomatic carriers, with a predilection for proximal and entrapment sites. Conclusions: These findings support the utility of nerve ultrasound as a non-invasive biomarker for early nerve involvement in ATTRv. Further studies are warranted to validate its role in disease monitoring and guide therapeutic interventions, especially in genetically at-risk populations.
- Open Access
- 30 August 2023
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 81 (08) , 764-775
Definitions, phenomenology, diagnosis, and management of the disorders of laughter and crying in amyotrophic lateral sclerosis (ALS): Consensus from ALS and Motor Neuron Disease Scientific Department of the Brazilian Academy of Neurology
The spectrum of neuropsychiatric phenomena observed in amyotrophic lateral sclerosis (ALS) is wide and not fully understood. Disorders of laughter and crying stand among the most common manifestations. The aim of this study is to report the results of an educational consensus organized by the Brazilian Academy of Neurology to evaluate the definitions, phenomenology, diagnosis, and management of the disorders of laughter and crying in ALS patients. Twelve members of the Brazilian Academy of Neurology - considered to be experts in the field - were recruited to answer 12 questions about the subject. After exchanging revisions, a first draft was prepared. A face-to-face meeting was held in Fortaleza, Brazil on 9.23.22 to discuss it. The revised version was subsequently emailed to all members of the ALS Scientific Department from the Brazilian Academy of Neurology and the final revised version submitted for publication. The prevalence of pseudobulbar affect/pathological laughter and crying (PBA/PLC) in ALS patients from 15 combined studies and 3906 patients was 27.4% (N = 1070), ranging from 11.4% to 71%. Bulbar onset is a risk factor but there are limited studies evaluating the differences in prevalence among the different motor neuron diseases subtypes, including patients with and without frontotemporal dementia. Antidepressants and a combination of dextromethorphan and quinidine (not available in Brazil) are possible therapeutic options. This group of panelists acknowledge the multiple gaps in the current literature and reinforces the need for further studies.
- 30 August 2023
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 81 (08) , 764-775
Open AccessDefinitions, phenomenology, diagnosis, and management of the disorders of laughter and crying in amyotrophic lateral sclerosis (ALS): Consensus from ALS and Motor Neuron Disease Scientific Department of the Brazilian Academy of Neurology
The spectrum of neuropsychiatric phenomena observed in amyotrophic lateral sclerosis (ALS) is wide and not fully understood. Disorders of laughter and crying stand among the most common manifestations. The aim of this study is to report the results of an educational consensus organized by the Brazilian Academy of Neurology to evaluate the definitions, phenomenology, diagnosis, and management of the disorders of laughter and crying in ALS patients. Twelve members of the Brazilian Academy of Neurology - considered to be experts in the field - were recruited to answer 12 questions about the subject. After exchanging revisions, a first draft was prepared. A face-to-face meeting was held in Fortaleza, Brazil on 9.23.22 to discuss it. The revised version was subsequently emailed to all members of the ALS Scientific Department from the Brazilian Academy of Neurology and the final revised version submitted for publication. The prevalence of pseudobulbar affect/pathological laughter and crying (PBA/PLC) in ALS patients from 15 combined studies and 3906 patients was 27.4% (N = 1070), ranging from 11.4% to 71%. Bulbar onset is a risk factor but there are limited studies evaluating the differences in prevalence among the different motor neuron diseases subtypes, including patients with and without frontotemporal dementia. Antidepressants and a combination of dextromethorphan and quinidine (not available in Brazil) are possible therapeutic options. This group of panelists acknowledge the multiple gaps in the current literature and reinforces the need for further studies.
- Open Access
- 8 August 2022
- Published by Springer Nature in Neurological Sciences
- Vol. 43 (10) , 1-2
Letter response to “The Janus faces of SARS-COV-2 infection in myasthenia gravis and myasthenic crisis”
- 8 August 2022
- Published by Springer Nature in Neurological Sciences
- Vol. 43 (10) , 1-2
Open AccessLetter response to “The Janus faces of SARS-COV-2 infection in myasthenia gravis and myasthenic crisis”
- Open Access
- 25 April 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (5)
A rara associação de dermatomiosite secundária à Chikungunya em fase crônica
A chikungunya é uma doença tropical infecciosa causada pelo vírus Chikungunya (CHIKV), um vírus de RNA da família Togaviridae, gênero Alphavirus. É transmitida por mosquitos do gênero Aedes, infectados com o CHIKV. A doença evolui em três fases: aguda, subaguda e crônica, esta última tendo início após 3 meses de sintomatologia. A mialgia é um dos sintomas mais prevalentes na doença podendo ser intensa. Na literatura, alguns casos de Miopatia secundária à Chikungunya em fase aguda foram descritos, porém poucos foram relatados na fase crônica da doença. Apresentamos o caso de uma paciente feminina, que em 2016 desenvolveu fraqueza muscular progressiva às custas de dermatomiosite após dois anos da infecção pelo CHIKV.
- 25 April 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (5)
Open AccessA rara associação de dermatomiosite secundária à Chikungunya em fase crônica
A chikungunya é uma doença tropical infecciosa causada pelo vírus Chikungunya (CHIKV), um vírus de RNA da família Togaviridae, gênero Alphavirus. É transmitida por mosquitos do gênero Aedes, infectados com o CHIKV. A doença evolui em três fases: aguda, subaguda e crônica, esta última tendo início após 3 meses de sintomatologia. A mialgia é um dos sintomas mais prevalentes na doença podendo ser intensa. Na literatura, alguns casos de Miopatia secundária à Chikungunya em fase aguda foram descritos, porém poucos foram relatados na fase crônica da doença. Apresentamos o caso de uma paciente feminina, que em 2016 desenvolveu fraqueza muscular progressiva às custas de dermatomiosite após dois anos da infecção pelo CHIKV.